Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAnthem Besponsa Coverage & Prior Auth Update | Ope…
    Ask Trek AI about this page
    CurrentAnthemPolicy CC-0131

    Besponsa (inotuzumab ozogamicin) Medical Drug Clinical Criteria

    Customize your policy alerts

    Sign up for Anthem Policy CC-0131 alerts

    Get alerted when Policy CC-0131 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical criteria governing prior authorization and medical necessity determinations for Besponsa (inotuzumab ozogamicin) use for CD22+ B-cell acute lymphoblastic leukemia (ALL), including frontline induction and relapsed/refractory settings; applies to Anthem members subject to medical benefit review.

    Policy Summary
    PayerAnthem
    PolicyBesponsa (inotuzumab ozogamicin) Medical Drug Clinical Criteria
    Policy CodePolicy CC-0131
    Change TypeClinical clarification and coding update
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionObtain prior authorization and submit documentation confirming CD22+ B-cell ALL diagnosis and the planned regimen (single-agent, TKI for Ph+ disease, or mini-hyper CVD with/without blinatumomab).
    SourceLink
    POLICY UPDATE CHANGES

    Updated combination with TKI to specify Philadelphia chromosome-positive disease and clarified frontline therapy may be used with or without blinatumomab.

    Removed ICD-10-CM D46.A and added C83.50-C83.59 to the coding list.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    black box
    Boxed warnings
    J9229HCPCS
    CD22+ ALLRequired diagnosis
    AllowedPediatric use

    Coverage Criteria for Besponsa (inotuzumab ozogamicin)

    Covered Indications (Initial and Frontline)

    Requests for Besponsa (inotuzumab ozogamicin) may be approved if the following criteria are met:

    Age or diagnosis: Individual is under 19 years of age

    Pediatric use allowed per NCCN; FDA approval is for adults but policy permits under-19 approval.

    Relapsed/Refractory pathway (adult): Individual has a diagnosis of CD22+ B-cell acute lymphocytic leukemia (ALL) AND relapsed or refractory disease

    Relapsed/refractory requirement applies to this pathway.

    Permitted regimens (label/NCCN): Use must be one of: single-agent Besponsa; OR Besponsa in combination with a tyrosine kinase inhibitor (bosutinib, dasatinib, imatinib, nilotinib, or ponatinib) for Philadelphia chromosome-positive B-ALL; OR Besponsa in combination with mini-hyper CVD (cyclophosphamide, dexamethasone, vincristine, methotrexate, cytarabine) with or without blinatumomab as consolidation therapy

    Combination regimens and consolidation/induction per label and NCCN are accepted.

    Frontline induction pathway: Individual has a diagnosis of CD22+ B-cell acute lymphocytic leukemia (ALL) (NCCN 2A) AND is using Besponsa as induction (frontline) therapy for Philadelphia chromosome-negative disease AND is using Besponsa in combination with mini-hyper CVD (with or without blinatumomab)

    Frontline induction use is limited to Ph-negative disease when given with mini-hyper CVD (blinatumomab optional).

    second-line | first-line

    Allowed lines: Relapsed/refractory setting for adults; OR frontline induction for Philadelphia chromosome-negative disease when used with mini-hyper CVD (with or without blinatumomab); OR pediatric use (individuals under 19)

    Policy allows both relapsed/refractory and specified frontline induction uses per NCCN.

    Requests for Besponsa (inotuzumab ozogamicin) for indications other than those explicitly listed in this policy are not approved. Coverage is limited to the specific diagnosis, age pathways, and regimen scenarios described in the criteria set.

    Requests that do not meet the required clinical criteria — including the specified diagnosis of CD22+ B-cell ALL, the applicable age pathway (pediatric pathway under 19 years when applicable versus relapsed/refractory pathway for adults), documented relapsed or refractory disease when required, or use of a permitted regimen (single-agent Besponsa; Besponsa + an approved TKI for Ph+ disease; or Besponsa + mini-hyper CVD with or without blinatumomab for the indicated frontline/consolidation uses) — may not be approved and can be denied as not medically necessary.

    RegimenDetails / Notes
    Single‑agent Besponsa (inotuzumab ozogamicin)Use as monotherapy per label and NCCN (relapsed/refractory CD22+ B‑cell ALL).
    Besponsa + tyrosine kinase inhibitor (bosutinib, dasatinib, imatinib, nilotinib, or ponatinib)Permitted for Philadelphia chromosome–positive (Ph+) B‑ALL per NCCN guidance (combination with a TKI).
    Besponsa + mini‑hyper CVD (cyclophosphamide, dexamethasone, vincristine, methotrexate, cytarabine) Permitted in combination with or without blinatumomab for consolidation or as induction for Philadelphia chromosome–negative (Ph‑) disease per NCCN; includes mini‑hyper CVD backbone details.

    Coding (HCPCS and ICD-10)

    HCPCSHCPCSCovered
    J9229Injection, inotuzumab ozogamicin, 0.1 mg [Besponsa]
    ICD-10 Diagnosis (included)ICD-10
    C83.50-C83.59Lymphoblastic (diffuse) lymphoma
    ICD-10 Diagnosis (included)ICD-10Covered
    C91.00-C91.02Acute lymphoblastic leukemia (ALL)

    Provider Actions, Documentation & Authorization

    Prior Authorization

    Prior authorization required — approval contingent on meeting clinical criteria

    Prior authorization is required for Besponsa (inotuzumab ozogamicin); approval is contingent on meeting the policy's clinical criteria for age or CD22+ B-cell ALL diagnosis, relapsed/refractory status or permitted frontline regimen, and the specified permitted regimens.

    • Submit PA for HCPCS J9229 (Injection, inotuzumab ozogamicin, 0.1 mg).
    Step Therapy

    No explicit step therapy — NCCN regimens permitted

    No explicit step therapy sequence is required by this policy; allowed regimens follow NCCN recommendations and include single-agent Besponsa or specified combination regimens without requiring prior alternatives.

    • Permitted regimens: single-agent Besponsa; Besponsa + a TKI (bosutinib, dasatinib, imatinib, nilotinib, ponatinib) for Ph+ disease; Besponsa + mini‑hyper CVD with or without blinatumomab.

    Biomarker Requirements

    inv-15: CD22 — requirement for CD22-positive B-cell ALL.
    Biomarker requirementCD22-positive B-cell acute lymphoblastic leukemia (ALL) is required for coverage; Besponsa targets CD22 and should only be used in CD22+ B-cell ALL.
    Clinical settingCoverage applies for relapsed or refractory disease in adults and for pediatric patients (<19 years) per NCCN guidance.
    Regimen contextUse may be single-agent or in specified combinations (e.g., with TKIs for Ph+ disease or with mini-hyper CVD for Ph– induction) as supported by NCCN.
    Coding supportDocumentation should include appropriate ICD-10 diagnosis codes for ALL (C91.00-C91.02) or lymphoblastic lymphoma codes as applicable.

    Background

    Besponsa (inotuzumab ozogamicin) is an anti-CD22 antibody–drug conjugate that delivers a cytotoxic payload to CD22-expressing B-cell precursor leukemias. Its use in this policy is limited to CD22-positive B-cell acute lymphoblastic leukemia (ALL) in the relapsed/refractory setting for adults and in specified frontline induction or consolidation regimens per NCCN recommendations.

    Definitions and Safety Terms

    inv-12: First-line/Second-line/Third-line therapy definitions as provided — render line-of-therapy definitions.
    First-line therapyThe first or primary treatment for the diagnosis (may include surgery, chemotherapy, radiation, or combinations).
    Second-line therapyTreatment given when initial (first-line) therapy is not effective or disease progresses.
    Third-line therapyTreatment given when both first- and second-line therapies are not effective or disease progresses.
    Safety note (VOD/SOS)Besponsa carries a boxed warning for hepatotoxicity including veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS); risk is higher after HSCT and Besponsa must be discontinued if VOD occurs.
    inv-13: VOD / SOS — definition and safety note about veno-occlusive disease / sinusoidal obstruction syndrome (boxed warning).
    Definition

    Revision History

    2026-02-20operational coding update

    Document history notes removal of ICD-10-CM D46.A and addition of C83.50–C83.59 to the coding list.

    2026-02-20clinical wording updateLatest

    Clinical wording clarified to specify that combination with a tyrosine kinase inhibitor applies to Philadelphia chromosome–positive disease and that frontline induction may be used with or without blinatumomab per NCCN guidance.

    Policy Summary
    PayerAnthem
    PolicyBesponsa (inotuzumab ozogamicin) Medical Drug Clinical Criteria
    Policy CodePolicy CC-0131
    Change TypeClinical clarification and coding update
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionObtain prior authorization and submit documentation confirming CD22+ B-cell ALL diagnosis and the planned regimen (single-agent, TKI for Ph+ disease, or mini-hyper CVD with/without blinatumomab).
    SourceLink
    On This Page
    Coverage Criteria for Besponsa (inotuzumab ozogamicin)Coding (HCPCS and ICD-10)Provider Actions, Documentation & AuthorizationBiomarker RequirementsBackgroundDefinitions and Safety TermsRevision History
    Documentation Required

    Required documentation to support diagnosis and planned regimen

    Provide documentation that establishes a CD22+ B-cell ALL diagnosis and the clinical rationale for Besponsa use consistent with policy pathways (pediatric under‑19 pathway, relapsed/refractory pathway, or frontline induction pathway with mini‑hyper CVD).

    • Relevant ICD-10 diagnosis codes (e.g., C91.00-C91.02 for ALL; C83.50-C83.59 as applicable).
    • Clinical notes documenting CD22 positivity and whether the disease is relapsed or refractory, or documentation supporting frontline induction use with mini‑hyper CVD (with/without blinatumomab) for Ph‑negative disease.
    • Planned regimen details (single-agent vs. specified combination and TKI selection if Ph‑positive).
    Denial Risk

    Denial triggers — criteria not met or unsupported indication

    Requests may be denied if the clinical criteria in the policy are not met or if the indication is not one of those listed (including failure to document CD22+ B-cell ALL, relapsed/refractory status when required, or permitted regimen).

    • Missing evidence of CD22‑positive B‑cell ALL.
    • No documentation of relapsed or refractory disease when not eligible via the pediatric (<19) pathway.
    • Use as frontline induction for Ph‑negative disease without combination with mini‑hyper CVD (with or without blinatumomab) as specified.
    Veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a potentially fatal hepatotoxicity associated with Besponsa (inotuzumab ozogamicin).
    Risk factorsRisk of VOD/SOS is greater in patients who undergo hematopoietic stem cell transplant (HSCT) after Besponsa; other risks include pre-existing liver disease, older age, later salvage lines, and more treatment cycles.
    Action if occursBesponsa should be permanently discontinued if VOD/SOS occurs.
    Post-HSCT mortalityBesponsa has a boxed warning for increased post-HSCT non-relapse mortality (higher day-100 post-HSCT mortality observed).